Edwin Kim
Allergy & Immunology · Chapel Hill, NCNPI 1659577070
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,950 of the $29,054 with a category attached, or 65.2%. 7 manufacturers reported payments, led by Genentech, Inc. at 41.0% of the total. Reporting peaked in 2022 at $10,915 and has fallen 98.2% since, to $197 in 2025.
Across 40 payments — averaging $726.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$12K
- Alk-abello, Inc$8K
- Genentech USA, Inc.$8K
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$72
- CSL Behring$33
- plus $14 from 1 others
Across 87 payments — averaging $9708.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$356K
- Aimmune Therapeutics, Inc.$284K
- Regeneron$205K
What the payments were for
- Consulting fees$18,95065%
- Speaking & faculty fees$5,00017%
- Travel & lodging$3,84313%
- Food & beverage$1,2614%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 12 | $11,915 |
| Alk-abello, Inc | 6 | $8,024 |
| Genentech USA, Inc. | 7 | $7,740 |
| Novartis | 9 | $1,256 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| CSL Behring | 2 | $33 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$29,054 in reported general payments places this provider in the 80th percentile of 140 allergy & immunology providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 18 | $58,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech, Inc.Xolair | $11,915 | $58,58418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Chapel Hill
- Scott ComminsChapel Hill$555K
- David FitzhughChapel Hill$104K
- Maeve OconnorCharlotte$2.2M
- Joel HartmanWinston Salem$749K
- Cristine RadojicicDurham$558K
- William McCannAsheville$486K
- Aerik WilliamsSalisbury$298K
- Karen DunnRaleigh$258K
- Roopen PatelCharlotte$257K
- Jonathan RomeoRaleigh$230K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.